论文部分内容阅读
本文报告了以 B663治疗在联合王国的、多种种族和国籍的31例瘤型或界线类-瘤型麻风病人。从临床及病理方面经12年的随访观察,可确定其是有进步的。并且对 DDS 耐受性病人和消退麻风反应(包括 ENL)方面,均具有显著的疗效。对4例有 ENL 反应的病人,以高剂量 B663治疗数月,均出现色素沉着。其余病人的剂量为每周三次,每次100mg,则无明显的色素沉着。在治疗期间,没有一例病人出现胃肠症状或体征。许多接受试验的病人于1940年代即开始以 DDS,其中又有多数病人曾经接受过多种药物长期的、复杂的和不满意的治疗,因而,这些情况对于 B663疗效的确定,也带来一些困难。一般的印象是,B663对麻风杆菌感染和消退麻风反应方面,均具有显著的价值。在观察研究期间,没有一例复发。故著者认为,至今尚没有一种其他通用的抗麻药物会有如此良好的疗效。
This article reports on 31 B-type and nontumor-type leprosy patients treated with B663 in the United Kingdom of various races and nationalities. From the clinical and pathological 12-year follow-up observation, we can determine that it is progress. And has significant efficacy in DDS-tolerant patients and in antifeedantal response (including ENL). In 4 patients with ENL response to high doses of B663 treatment for several months, were hyperpigmentation. The rest of the patient’s dose three times a week, each 100mg, no significant pigmentation. During the treatment, none of the patients had gastrointestinal symptoms or signs. Many of the patients who were tested started DDS in the 1940s, and many of them had long-term, complicated and unsatisfactory treatment of many types of drugs and therefore these conditions also caused some difficulties in determining the efficacy of B663 . The general impression is that B663 has significant value for both the infection with Leprosy and the withdrawal of leprosy. No recurrence occurred during the observation study. Therefore, the author believes that so far there is no other generic anti-malaria drugs will have such a good effect.